FDA Approves Oxlumo (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1
The Pharma Data
NOVEMBER 24, 2020
0.514 mmol/24 hr/1.73 0.771 mmol/24 hr/1.73 About RNAi RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Visit OXLUMO.com for more information, including full Prescribing Information.
52 
Let's personalize your content